Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | TERT | O14746 | 3/20 | 0.36 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.36 |
| ▸ | CD40 | P25942 | 2/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.34 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.34 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.34 |
| ▸ | GHSR | Q92847 | 1/20 | 0.34 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.33 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.33 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.33 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.33 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.33 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7160638 | 1.00 | MMP2 (0.37) | MMP2TERTSLC15A2CD40DPP8 | |
| SCHEMBL10525648 | 0.97 | CD40 (0.33) | MMP2TERTSLC15A2CD40DPP8 | |
| SCHEMBL9616877 | 0.92 | MMP2 (0.39) | MMP2TERTSLC15A2CD40DPP8 | |
| SCHEMBL9200315 | 0.92 | MMP2 (0.39) | MMP2TERTSLC15A2CD40DPP8 | |
| SCHEMBL8427968 | 0.92 | MMP2 (0.39) | MMP2TERTSLC15A2CD40DPP8 | |
| SCHEMBL9183876 | 0.90 | MMP2 (0.36) | MMP2TERTSLC15A2CD40DPP8 | |
| SCHEMBL18568245 | 0.89 | MMP2 (0.35) | MMP2TERTSLC15A2CD40DPP8 | |
| SCHEMBL29484171 | 0.89 | SLC15A2 (0.41) | MMP2TERTSLC15A2CD40GHSR | |
| SCHEMBL10524626 | 0.87 | SIRT6 (0.43) | SLC15A2 | |
| SCHEMBL10524634 | 0.87 | SIRT6 (0.43) | SLC15A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0506628-B1 | Aminoacyl and oligopeptidyl derivatives of allopurinol exhibiting immunostimulatory activity, and pharmaceutical formulations containing these substances | SIGMA TAU IND FARMACEUTI (IT) | 1996-09-18 | — | — | EP | claimed |
| EP-0506628-A2 | Aminoacyl and oligopeptidyl derivatives of allopurinol exhibiting immunostimulatory activity, and pharmaceutical formulations containing these substances | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1992-09-30 | — | — | EP | claimed |
| EP-0464009-A2 | Oligopeptide derivatives of ipoxantine endowed with immunomodulating activity and pharmaceutical compositions containing same | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1992-01-02 | — | — | EP | claimed |
| US-20030186998-A1 | Methods for treatment of disorders of cardiac contractility | JOHN HOPKINS UNIVERSITY | 2003-10-02 | — | — | US | disclosed |
| US-6569862-B1 | Adminstering xanthine oxidase inhibitor such as allopurinol | JOHNS HOPKINS UNIVERSITY | 2003-05-27 | — | — | US | disclosed |
| EP-1044002-A4 | METHODS FOR TREATMENT OF DISORDERS OF CARDIAC CONTRACTILITY | UNIV JOHNS HOPKINS (US) | 2003-05-02 | — | — | EP | disclosed |
| US-6191136-B1 | ADMINISTERING XANTHINE OXIDASE INHIBITOR | JOHNS HOPKINS UNIVERSITY | 2001-02-20 | — | — | US | disclosed |
| EP-1044002-A1 | METHODS FOR TREATMENT OF DISORDERS OF CARDIAC CONTRACTILITY | JOHNS HOPKINS UNIVERSITY (US) | 2000-10-18 | — | — | EP | disclosed |
| WO-1999024038-A1 | METHODS FOR TREATMENT OF DISORDERS OF CARDIAC CONTRACTILITY | JOHNS HOPKINS UNIVERSITY (US) | 1999-05-20 | — | — | WO | disclosed |
| EP-0506628-B1 | Aminoacyl and oligopeptidyl derivatives of allopurinol exhibiting immunostimulatory activity, and pharmaceutical formulations containing these substances | SIGMA TAU IND FARMACEUTI (IT) | 1996-09-18 | — | — | EP | disclosed |
| US-5298621-A | Peptides endcapped with purine derivative | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1994-03-29 | — | — | US | disclosed |
| US-5298621-A | Peptides endcapped with purine derivative | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1994-03-29 | — | — | US | disclosed |
| US-5272151-A | Aminoacyl and oligopeptidyl derivatives of allopurinol exhibiting immunostimulatory activity, and pharmaceutical formulations containing these substances | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1993-12-21 | — | — | US | disclosed |
| US-5272151-A | Aminoacyl and oligopeptidyl derivatives of allopurinol exhibiting immunostimulatory activity, and pharmaceutical formulations containing these substances | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1993-12-21 | — | — | US | disclosed |
| EP-0514460-A1 | ANTI-OXIDATIVE AND ANTI-INFLAMMATORY METAL:PEPTIDE COMPLEXES AND USES THEREOF | PROCYTE CORPORATION (US) | 1992-11-25 | — | — | EP | disclosed |
| EP-0506628-A3 | AMINOACYL AND OLIGOPEPTIDYL DERIVATIVES OF ALLOPURINOL EXHIBITING IMMUNOSTIMULATORY ACTIVITY, AND PHARMACEUTICAL FORMULATIONS CONTAINING THESE SUBSTANCES | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1992-10-21 | — | — | EP | disclosed |
| EP-0506628-A2 | Aminoacyl and oligopeptidyl derivatives of allopurinol exhibiting immunostimulatory activity, and pharmaceutical formulations containing these substances | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1992-09-30 | — | — | EP | disclosed |
| EP-0464009-A2 | Oligopeptide derivatives of ipoxantine endowed with immunomodulating activity and pharmaceutical compositions containing same | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1992-01-02 | — | — | EP | disclosed |
| EP-0464009-A2 | Oligopeptide derivatives of ipoxantine endowed with immunomodulating activity and pharmaceutical compositions containing same | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1992-01-02 | — | — | EP | disclosed |
| WO-1991012267-A1 | ANTI-OXIDATIVE AND ANTI-INFLAMMATORY METAL:PEPTIDE COMPLEXES AND USES THEREOF | PROCYTE CORPORATION (US) | 1991-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186998-A1 | Methods for treatment of disorders of cardiac contractility | TNNI3, TNNT2, RYR2 | MMP2 1203/4885TERT 4361/4885SLC15A2 1903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.